PFS rates at 2 y
| Arm/group . | N . | No. of successes* . | % . | Exact 90% CI, % . |
|---|---|---|---|---|
| A: FR, non-del(11q) | 123 | 79 | 64 | 57-71 |
| B: FR + L, non-del(11q) | 109 | 79 | 72 | 65-79 |
| C: FCR, non-del(11q) | 110 | 81 | 74 | 66-80 |
| C: FCR, del(11q) | 27 | 15 | 56 | 38-72 |
| D: FCR + L, del(11q) | 31 | 20 | 65 | 48-79 |
| Arm/group . | N . | No. of successes* . | % . | Exact 90% CI, % . |
|---|---|---|---|---|
| A: FR, non-del(11q) | 123 | 79 | 64 | 57-71 |
| B: FR + L, non-del(11q) | 109 | 79 | 72 | 65-79 |
| C: FCR, non-del(11q) | 110 | 81 | 74 | 66-80 |
| C: FCR, del(11q) | 27 | 15 | 56 | 38-72 |
| D: FCR + L, del(11q) | 31 | 20 | 65 | 48-79 |
Patients lost to follow-up, starting nonprotocol therapy, or with progressions or deaths prior to 2 years were treated as failures.